pharmaphorum| News & views on pharma and biotech’s evolving future

R&D

Go north: Life sciences excellence shines bright in Sweden

Gothenburg is Sweden's fastest-growing and second largest city region and one of Europe's leading innovation regions.

News

Non-profit DNDi preps phase 3 trials for dengue antibody

Non-profit DNDi has licensed a dengue therapy from India's SII, paving the way for a phase 3 trial in Malaysia, Thailand, and Brazil.

Oncology

Oncology 2026

Patients

End-of-life choice means little without end-of-life support

A strong end-of-life care system does not wait until the final days to step in.

News

Bausch + Lomb drug fails in glaucoma, but a new use beckons

Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to abandon BL117 for glaucoma.

Featured Content

Patients

End-of-life choice means little without end-of-life support

A strong end-of-life care system does not wait until the final days to step in.

Oncology

Oncology 2026

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

R&D

pharmaphorum podcast Episode 267, Haseeb Ahmad - Purespring Therapeutics

Purespring on nephrology & gene therapy in kidney disease

Purespring CEO Haseeb Ahmad discusses transforming the treatment of kidney disease, an area of enormous unmet need, and the company's gene therapy.

Patients

ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee

A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Newsletters and Deep Dive
digital magazine

Latest News

News

Non-profit DNDi preps phase 3 trials for dengue antibody

Non-profit DNDi has licensed a dengue therapy from India's SII, paving the way for a phase 3 trial in Malaysia, Thailand, and Brazil.

News

Bausch + Lomb drug fails in glaucoma, but a new use beckons

Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to abandon BL117 for glaucoma.

News

Roche abandons two Huntington's drug candidates

Roche has scrapped two drugs for Huntington's disease – tominersen and RG6496 – after seeing disappointing results in clinical trials.

News

Bayer gets €3bn from Apollo for contraceptives unit stake

Bayer has partnered with private equity group Apollo to set up a new entity that will handle its long-acting contraceptives products.

Views & Analysis

Patients

End-of-life choice means little without end-of-life support

A strong end-of-life care system does not wait until the final days to step in.

R&D

Go north: Life sciences excellence shines bright in Sweden

Gothenburg is Sweden's fastest-growing and second largest city region and one of Europe's leading innovation regions.

Sales & Marketing

Is pure play pharma's new pharmakon?

The shift in commercial teams has been happening for some time. This is not new news. I have felt it many times over, like many of us who have worked in the industry for years.

Patients

ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee

A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

Oncology

How IRA, MFN, and HTA are rewriting oncology launch strategy...

Oncology

Solving the ovarian cancer diagnostic and treatment pathway ...

Oncology

Early onset cancer new approach treatment

White Papers & Webinar

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Podcasts & Video

Patients

ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee

A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.

R&D

Purespring on nephrology & gene therapy in kidney disease

Purespring CEO Haseeb Ahmad discusses transforming the treatment of kidney disease, an area of enormous unmet need, and the company's gene therapy.

R&D

pharmaphorum podcast Episode 266, Parexel - Paul Bridges and Charlotte Moser

Parexel: Flawless execution, policy shifts & patient-centric...

Parexel's Paul Bridges & Charlotte Moser discuss Europe's biotech sector in the face of an innovation cliff.

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

Partner Content

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Event

Partner Content

Register Now for AAPS PharmSci 360!

Learn from pharmaceutical scientists involved at every stage of the drug development pipeline at PharmSci 360.

Event

Partner Content

16th World Clinical Biomarkers & CDx Summit

The globe’s longest-standing, industry-dedicated forum for precision medicine is back.

Press Releases

Partner Content

Inizio Launches Intelligent Congress to Turn Event Investmen...

Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress

Event

Partner Content

17th World ADC San Diego | October 12-15, 2026

The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes

Featured Content

Editor's Picks

Latest News

Views & Analysis

Deep Dive

White Papers & Webinar

Podcasts & Video

Partner Content